Skip to main content
Premium Trial:

Request an Annual Quote

As Expected, Nasdaq Says Tripos is 'Shell,' Threatens Delisting

NEW YORK (GenomeWeb News) — Nasdaq has notified Tripos that it can be delisted from the Nasdaq Global Market and from the Nasdaq Stock Market because it has become a “public shell” after selling its Discovery Research and Discovery Informatics branches.
Tripos, which said it has been anticipating the notice, said it will meet with the exchange June 28 to review the matter.
Tripos has been executing a liquidation plan since last year. Nasdaq said it may delist the company because Tripos “is not currently engaged in an active business operation” and is now a public shell.
Tripos said today it is “actively engaged” in trying to have its stock listed on the OTC Bulletin Board after Nasdaq delists it.
If that option fails Tripos said it will close its stock transfer books.
The Scan

Missed Early Cases

A retrospective analysis of blood samples suggests early SARS-CoV-2 infections may have been missed in the US, the New York Times reports.

Limited Journal Editor Diversity

A survey finds low diversity among scientific and medical journal editors, according to The Scientist.

How Much of a Threat?

Science writes that need for a provision aimed at shoring up genomic data security within a new US bill is being questioned.

PNAS Papers on Historic Helicobacter Spread, Brain Development, C. difficile RNAs

In PNAS this week: Helicobacter genetic diversity gives insight into human migrations, gene expression patterns of brain development, and more.